284 related articles for article (PubMed ID: 30836915)
1. Screening of Anti-mycobacterial Phytochemical Compounds for Potential Inhibitors against Mycobacterium Tuberculosis Isocitrate Lyase.
Tiwari A; Kumar A; Srivastava G; Sharma A
Curr Top Med Chem; 2019; 19(8):600-608. PubMed ID: 30836915
[TBL] [Abstract][Full Text] [Related]
2. Structure-based screening and molecular dynamics simulations offer novel natural compounds as potential inhibitors of Mycobacterium tuberculosis isocitrate lyase.
Shukla R; Shukla H; Sonkar A; Pandey T; Tripathi T
J Biomol Struct Dyn; 2018 Jun; 36(8):2045-2057. PubMed ID: 28605994
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
[TBL] [Abstract][Full Text] [Related]
4. Alternate pathway to ascorbate induced inhibition of Mycobacterium tuberculosis.
Shukla H; Khan SR; Shukla R; Krishnan MY; Akhtar MS; Tripathi T
Tuberculosis (Edinb); 2018 Jul; 111():161-169. PubMed ID: 30029903
[TBL] [Abstract][Full Text] [Related]
5. Isocitrate lyase of Mycobacterium tuberculosis is inhibited by quercetin through binding at N-terminus.
Shukla H; Kumar V; Singh AK; Rastogi S; Khan SR; Siddiqi MI; Krishnan MY; Akhtar MS
Int J Biol Macromol; 2015; 78():137-41. PubMed ID: 25869309
[TBL] [Abstract][Full Text] [Related]
6. Applications of Ensemble Docking in Potential Inhibitor Screening for Mycobacterium tuberculosis Isocitrate Lyase Using a Local Plant Database.
Lee YV; Choi SB; Wahab HA; Lim TS; Choong YS
J Chem Inf Model; 2019 May; 59(5):2487-2495. PubMed ID: 30840452
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a Novel Inhibitor Structure of
Duan C; Jiang Q; Jiang X; Zeng H; Wu Q; Yu Y; Yang X
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458645
[TBL] [Abstract][Full Text] [Related]
8.
Joshi T; Joshi T; Sharma P; Pundir H; Chandra S
J Biomol Struct Dyn; 2021 Aug; 39(13):4816-4834. PubMed ID: 32568603
[TBL] [Abstract][Full Text] [Related]
9. Virtual screening to identify novel potential inhibitors for Glutamine synthetase of
Kumari M; Subbarao N
J Biomol Struct Dyn; 2020 Oct; 38(17):5062-5080. PubMed ID: 31755360
[TBL] [Abstract][Full Text] [Related]
10. Targeting isocitrate lyase for the treatment of latent tuberculosis.
Bhusal RP; Bashiri G; Kwai BXC; Sperry J; Leung IKH
Drug Discov Today; 2017 Jul; 22(7):1008-1016. PubMed ID: 28458043
[TBL] [Abstract][Full Text] [Related]
11. 5-Nitro-2,6-dioxohexahydro-4-pyrimidinecarboxamides: synthesis, in vitro antimycobacterial activity, cytotoxicity, and isocitrate lyase inhibition studies.
Sriram D; Yogeeswari P; Senthilkumar P; Naidu G; Bhat P
J Enzyme Inhib Med Chem; 2010 Dec; 25(6):765-72. PubMed ID: 20569083
[TBL] [Abstract][Full Text] [Related]
12. Drug targeted virtual screening and molecular dynamics of LipU protein of Mycobacterium tuberculosis and Mycobacterium leprae.
Kaur G; Pandey B; Kumar A; Garewal N; Grover A; Kaur J
J Biomol Struct Dyn; 2019 Mar; 37(5):1254-1269. PubMed ID: 29557724
[TBL] [Abstract][Full Text] [Related]
13. Advances in mycobacterial isocitrate lyase targeting and inhibitors.
Krátký M; Vinšová J
Curr Med Chem; 2012; 19(36):6126-37. PubMed ID: 23092127
[TBL] [Abstract][Full Text] [Related]
14. Identification of potential inhibitors for mycobacterial uridine diphosphogalactofuranose-galactopyranose mutase enzyme: A novel drug target through in silico approach.
Nayak T; Jena L; Waghmare P; Harinath BC
Int J Mycobacteriol; 2018; 7(1):61-68. PubMed ID: 29516888
[TBL] [Abstract][Full Text] [Related]
15. Alterations in conformational topology and interaction dynamics caused by L418A mutation leads to activity loss of Mycobacterium tuberculosis isocitrate lyase.
Shukla H; Shukla R; Sonkar A; Tripathi T
Biochem Biophys Res Commun; 2017 Aug; 490(2):276-282. PubMed ID: 28610921
[TBL] [Abstract][Full Text] [Related]
16. Identification of potent L,D-transpeptidase 5 inhibitors for Mycobacterium tuberculosis as potential anti-TB leads: virtual screening and molecular dynamics simulations.
Sabe VT; Tolufashe GF; Ibeji CU; Maseko SB; Govender T; Maguire GEM; Lamichhane G; Honarparvar B; Kruger HG
J Mol Model; 2019 Oct; 25(11):328. PubMed ID: 31656981
[TBL] [Abstract][Full Text] [Related]
17. Activity loss by H46A mutation in Mycobacterium tuberculosis isocitrate lyase is due to decrease in structural plasticity and collective motions of the active site.
Shukla R; Shukla H; Tripathi T
Tuberculosis (Edinb); 2018 Jan; 108():143-150. PubMed ID: 29523315
[TBL] [Abstract][Full Text] [Related]
18. Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis.
Kumar S; Mehra R; Sharma S; Bokolia NP; Raina D; Nargotra A; Singh PP; Khan IA
Tuberculosis (Edinb); 2018 Jan; 108():56-63. PubMed ID: 29523328
[TBL] [Abstract][Full Text] [Related]
19. Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
Krátký M; Janďourek O; Baranyai Z; Novotná E; Stolaříková J; Bősze S; Vinšová J
Eur J Med Chem; 2019 Nov; 181():111578. PubMed ID: 31401536
[TBL] [Abstract][Full Text] [Related]
20. Isocitrate lyase: a potential target for anti-tubercular drugs.
Sharma R; Das O; Damle SG; Sharma AK
Recent Pat Inflamm Allergy Drug Discov; 2013 May; 7(2):114-23. PubMed ID: 23506018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
